A pragmatic regulatory approach for complex generics through the U.S. FDA 505(j) or 505(b)(2) approval pathways
暂无分享,去创建一个
G. Borchard | S. McNeil | Vinod Shah | K. Klein | B. Flühmann | J. S. D. de Vlieger | Vinod P. Shah | Kevin Klein | Jon S. B. de Vlieger